NUTRITIONAL FORMULATIONS INCLUDING HUMAN MILK OLIGOSACCHARIDES AND ANTIOXIDANTS AND USES THEREOF

• US 20120172327A1
• Filed: 12/22/2011
• Published: 07/05/2012
• Est. Priority Date: 12/31/2010
• Status: Active Grant

• Current Assignee: Abbott Laboratories Incorporated
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Buck, Rachael, Duska-McEwen, Geralyn O., Schaller, Joseph P.
• Granted Patent: US 8,703,737 B2
• Time in Patent Office: Days
• US Class Current: 514/54
• CPC Class Codes: A23L 33/12 Fatty acids or derivatives thereof
• CPC Class Codes: A23L 33/40 Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/3202 Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
• CPC Class Codes: A23V 2200/324 having an effect on the immune system
• CPC Class Codes: A23V 2250/1882 Polyunsaturated fatty acids
• CPC Class Codes: A23V 2250/28 Oligosaccharides
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/7016 Disaccharides, e.g. lactose, lactulose lactobionic acid A61K31/7032
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants

Abstract

Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

Claims

1. A synthetic pediatric formula comprising a human milk oligosaccharide and from about 0.025 μ

g/mL to about 0.130 μ

g/mL of a long chain polyunsaturated fatty acid.

2. The synthetic pediatric formula of claim 1, wherein the human milk oligosaccharide is selected from the group consisting of 6′

-sialyllactose, 2′

-fucosyllactose, and combinations thereof and the long chain polyunsaturated fatty acid is selected from the group consisting of linoleic acid, linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid, and combinations thereof.

3. The synthetic pediatric formula of claim 2, wherein the long chain polyunsaturated fatty acid is docosahexaenoic acid.

4. The synthetic pediatric formula of claim 2, wherein the human milk oligosaccharide is 6′

-sialyllactose.

5. The synthetic pediatric formula of claim 4, wherein the 6′

-sialyllactose is present in a concentration of from about 0.001 μ

g/mL to about 20 μ

g/mL.

6. The synthetic pediatric formula of claim 5, wherein the 6′

-sialyllactose is present in a concentration of from about 0.001 μ

g/mL to less than 0.25 μ

g/mL.

7. The synthetic pediatric formula of claim 5, wherein the 6′

-sialyllactose is present in a concentration of from greater than 0.4 μ

g/mL to 20 μ

g/mL.

8. The synthetic pediatric formula of claim 2, wherein the human milk oligosaccharide is 2′

-fucosyllactose.

9. The synthetic pediatric formula of claim 8, wherein the 2′

fucosyllactose is present in a concentration of from about 0.001 μ

g/mL to about 1 μ

g/mL.

10. A synthetic pediatric formula comprising a human milk oligosaccharide and from about 0.001 μ

g/mL to about 10 μ

g/mL of a carotenoid.

11. The synthetic pediatric formula of claim 10, wherein the carotenoid is present in a concentration of from about 0.001 μ

g/mL to about 5 μ

g/mL.

12. The synthetic pediatric formula of claim 10, wherein the human milk oligosaccharide is selected from the group consisting of 6′

-sialyllactose, 2′

-fucosyllactose, and combinations thereof and the carotenoid is selected from the group consisting of lutein, lycopene, beta-carotene, and combinations thereof.

13. The synthetic pediatric formula of claim 12, wherein the human milk oligosaccharide is 2′

-fucosyllactose and the carotenoid is lycopene.

14. The synthetic pediatric formula of claim 13, wherein the 2′

-fucosyllactose is present in a concentration of from about 0.001 μ

g/mL to about 1 μ

g/mL.

15. A method of reducing inflammation in an infant, toddler, or child in need thereof, the method comprising administering to the infant, child or toddler a composition comprising a human milk oligosaccharide and from about 0.025 μ

g/mL to about 0.130 mg/mL of a long chain polyunsaturated fatty acid.

16. The method of claim 15, wherein the human milk oligosaccharide is selected from the group consisting of 6′

-sialyllactose, 2′

-fucosyllactose, and combinations thereof and the long chain polyunsaturated fatty acid is selected from the group consisting of linoleic acid, linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid, and combinations thereof.

17. The method of claim 15, wherein the long chain polyunsaturated fatty acid is docosahexaenoic acid.

18. The method of claim 15, wherein the human milk oligosaccharide is 6′

-sialyllactose.

19. The method of claim 18, wherein the 6′

-sialyllactose is present in a concentration of from about 0.001 μ

g/mL to about 20 μ

g/mL.

20. The method of claim 19, wherein the 6′

-sialyllactose is present in a concentration of from about 0.001 μ

g/mL to less than 0.25 μ

g/mL.